Aviado · Research
Longevity Daily
Sunday, October 18, 2026
Listen
Today's Brief
Precision medicine takes center stage today: neurologist Richard Isaacson presents landmark evidence that personalized Alzheimer prevention protocols can measurably improve cognition — our must-read for anyone tracking dementia risk. The hype-versus-evidence gap runs through several other stories, from UK scientists systematically dismantling Bryan Johnson's £1.6M regimen to new data showing high-fiber diets outperforming metformin for blood sugar control. Aviado's deep dive on vinpocetine explains why it's the rare brain supplement with documented 20–37% cerebral blood flow improvements across multiple clinical trials. And the FDA's potential rollback of supplement warning labels deserves close attention from anyone who shops the supplement aisle.
10 stories1 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Personalized Alzheimer Prevention Protocols Can Measurably Improve Cognition, Isaacson Says
Neurologist Richard Isaacson, MD — one of the world's leading Alzheimer prevention researchers — says a landmark new study demonstrates that individually tailored lifestyle and supplement protocols can produce measurable cognitive improvements and meaningfully reduce Alzheimer disease risk, not just delay it. The work is a proof-of-concept for precision medicine in brain health: matching interventions to your specific biomarker profile, genetic risk factors, and metabolic status rather than applying generic advice. If you're already tracking APOE status, inflammation markers, or insulin sensitivity, this study signals those efforts are clinically meaningful — and that the specifics of your protocol matter enormously. It also reinforces why working with a clinician who understands your individual risk picture is more valuable than any single supplement or drug.
Read more →How Vinpocetine Boosts Cerebral Blood Flow by 20–37% — and Why That Matters for Brain Aging
Most nootropics work by tweaking neurotransmitters, but vinpocetine takes a fundamentally different approach: it blocks PDE1, the enzyme that constricts cerebral blood vessels, directly increasing circulation to the brain. Clinical trials show consistent blood flow improvements of 20–37%, particularly in the thalamus — the hub that governs attention and memory — with effects measurable within hours of dosing. Aviado's analysis supports 10–30 mg daily in divided doses with meals, matching the protocols used in successful trials, and flags this as one of the few nootropics where the vascular mechanism is reproducible across multiple independent studies.
Read the full Aviado analysis →Supplements & Compounds
Bausch + Lomb Adds B-Vitamin Complex to Gold-Standard Eye Supplement After Trial Links It to Reduced AMD Risk
Bausch + Lomb has launched PreserVision AREDS3, upgrading the long-established AREDS2 formula for age-related macular degeneration with a targeted B-vitamin complex. The reformulation is backed by data from the Women's Health Study Cardiovascular Study, which found a statistically significant association between specific B-vitamin supplementation and reduced AMD risk. If you or someone you care for is already on AREDS2, this evidence-backed upgrade is worth a conversation with your ophthalmologist.
Read more →Brain Imaging Reveals Where Kanna Supplement Hits the Brain — Within Hours of a Single Dose
A new neuroimaging study found that Sceletium tortuosum (kanna), a South African succulent extract, reduced activity in the amygdala — the brain's primary stress-signaling center — within hours of a single dose. The research, commissioned by PLT Health Solutions for their proprietary extract, is described as the first brain-imaging evidence pinpointing where the compound acts. The commercial sponsorship warrants caution: independent replication is needed, but the amygdala mechanism is biologically plausible and the speed of effect is notable for a botanical.
Read more →Research & Papers
Nighttime Heat Waves Age You Faster Than Daytime Heat, Large Cohort Study Finds
A Chinese national cohort study of over 8,000 adults found that nighttime and compound (day-and-night) heat waves accelerate biological aging significantly more than daytime heat exposure alone — with each additional day of nighttime heat linked to roughly 0.02 extra years of biological age in both cross-sectional (n=8,223) and longitudinal (n=5,047) analyses. Daytime heat alone showed much weaker and less consistent effects, suggesting it's the inability to cool down overnight that drives the aging signal. The practical takeaway: actively cooling your bedroom during heat events — fans, air conditioning, cool bedding — may be a meaningful and underrated longevity intervention.
Read more →2026's Landmark Longevity Trials: Rapamycin and Senolytics Deliver First Wave of Human Evidence
The PEARL trial — testing low-dose rapamycin in healthy older adults — and a senolytic study using dasatinib plus quercetin for liver disease are generating the first substantive human clinical evidence that pharmacological longevity interventions measurably work. These aren't preclinical findings: both programs are reporting improvements in aging-related biomarkers in people, representing a meaningful shift from the decades of promising mouse data that preceded them. For anyone following the rapamycin or senolytic space, 2026 is shaping up as the year longevity pharmacology earns its clinical credibility.
Read more →Lifestyle & Nutrition
High-Fiber Diet Beats Metformin for Blood Sugar Control and Weight Loss, Head-to-Head Study Finds
A head-to-head study found that a high-fiber diet outperformed metformin for managing blood sugar and promoting weight loss in people with diabesity — the combined condition of obesity and type 2 diabetes. Metformin is one of the most commonly used off-label longevity drugs, but this finding suggests that gut microbiome-modulating dietary fiber may be a more powerful first-line tool. If you're currently on metformin primarily for longevity purposes rather than diabetes management, this is worth raising with your doctor — the dietary lever may be doing more work than the pill.
Read more →UK Scientists Dismantle Bryan Johnson's £1.6M Anti-Aging Protocol — But Validate One Diet Pattern
A team of UK university scientists has published a detailed critique of Bryan Johnson's £1.6 million-per-year anti-aging regimen, arguing that much of the protocol lacks robust human evidence and that some biomarker improvements may reflect measurement artifacts rather than genuine rejuvenation. However, researchers validated one concrete element: a 6:1 fasting pattern (six days of normal eating, one day of fasting) showed real and reproducible metabolic benefits. If you've been tempted to replicate Johnson's full stack, this is a useful calibration — and a useful pointer toward what the evidence actually supports.
Read more →Industry & Policy
FDA Signals It May Drop Mandatory Disclaimer from Supplement Labels — A Win for Brands, a Warning for Consumers
The FDA's food division head has indicated the agency is considering eliminating the requirement that supplement labels repeatedly display the disclaimer stating products are "not intended to diagnose, treat, cure, or prevent any disease." The change would give supplement brands more marketing flexibility — but it also removes one of the few consistent consumer-facing signals that supplements operate under a different (and lighter) regulatory standard than drugs. For longevity supplement users already navigating an evidence-variable market, this shift means more due diligence falls on you, not the label.
Read more →Mark Wahlberg Bets Affordable Gyms Can Crack Open the Longevity-Optimization Market
Mark Wahlberg is launching a budget-friendly gym concept aimed squarely at the longevity-optimization market, currently dominated by premium membership clubs like Fountain Life — which charges up to $21,500 per year. The move signals that the longevity wellness space is maturing beyond ultra-wealthy early adopters and moving toward mainstream consumer access. Whether it delivers meaningful longevity outcomes or primarily longevity-branded fitness marketing remains to be tested, but the competitive pressure on high-end incumbents is real.
Read more →